Why the study?
Tobacco combustion exposure worsens rheumatoid arthritis, but the toxicity of emerging non-combustible heat-not-burn tobacco devices remains unclear.
Does heat-not-burn tobacco vapor or cigarette smoke exposure worsen antigen-induced arthritis in mice?
Does heat-not-burn tobacco vapor or cigarette smoke exposure worsen antigen-induced arthritis in mice?
Both cigarette smoke and heat-not-burn tobacco vapor inhalation exhibit toxic effects on the immune system in a murine model of rheumatoid arthritis.
May inform harm reduction choices in RA; hypothesis-generating from animal data and leaves open human relevance.
Tobacco combustion exposure worsens rheumatoid arthritis (RA). Non-combustible tobacco devices, as heat-not-burn tobacco (HNBT), are emerging as harm reduction to smokers by releasing nicotine and lower combustible tobacco products. Nevertheless, HNBT toxicity remains unclear. Hence, here we investigated the impacts of the tobacco combustible product (cigarette smoke; CS) or HNBT vapor exposures on antigen-induced arthritis (AIA) in C57BL/6 mice. Animals were exposed to airflow, HNBT vapor, or CS during 1 h/twice a day, under the Health Canada Intense (HCI) smoking regime, between days 14 to 20 after the first immunization. At day 21, 16 h after the last exposures, mice were i.a. challenged and the AIA effects were evaluated 24 h later. CS- or HNBT-exposed mice presented equivalent blood nicotine levels. CS exposure worsened articular symptoms, pulmonary inflammation, and expression of lung metallothioneins. Nevertheless, CS or HNBT exposures reduced lymphoid organs' cellularity, splenocyte proliferation and IL-2 secretion. Additional in vitro CS or HNBT exposures confirmed the harmful effects on splenocytes, which were partially mediated by the activation of nicotine/α7nAchR pathway. Associated, data demonstrate the toxic mechanisms of CS or HNBT inhalation at HCI regime on RA, and highlight that further investigations are fundamental to assure the toxicity of emerging tobacco products on the immune system during specific challenges.
No takes yet. Share an insight, caveat, or question.
Its licence doesn't allow us to show a copy here.
Heluany et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: